In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents
September 7th, 2022
1.6K views
This protocol describes the procedure for measuring ATP concentrations in the lumen of the bladder in an anesthetized rodent.
Overview
This protocol describes the procedure for measuring ATP concentrations in the lumen of the bladder in an anesthetized rodent. Our technique measures ATP directly from the bladder lumen, making it more physiologically relevant than techniques using cultured cells or bladder tissue.
Key Study Components
Area of Science
- Neuroscience
- Physiology
- Urology
Background
- ATP is an important transmitter in the urinary bladder.
- Understanding ATP release mechanisms is crucial for bladder function.
- Current methods may lack physiological relevance.
- This protocol aims to provide a more accurate measurement technique.
Purpose of Study
- To measure ATP concentrations in the bladder lumen.
- To investigate the mechanisms controlling ATP release.
- To improve upon existing measurement techniques.
Methods Used
- Induction of anesthesia using isoflurane.
- Subcutaneous administration of urethane.
- Monitoring anesthesia depth through foot pinch response.
- Direct measurement of ATP from the bladder lumen.
Main Results
- Successful measurement of ATP concentrations in vivo.
- Demonstration of the procedure by research technicians.
- Validation of the technique's physiological relevance.
- Potential implications for understanding bladder physiology.
Conclusions
- The protocol provides a reliable method for measuring ATP in the bladder.
- It enhances the understanding of ATP's role in bladder function.
- This approach may lead to new insights into urinary bladder physiology.
Frequently Asked Questions
What is the significance of measuring ATP in the bladder?
Measuring ATP helps understand its role as a transmitter in bladder function.
How does this method compare to previous techniques?
This method is more physiologically relevant than using cultured cells or tissue.
What is the role of urethane in this protocol?
Urethane is used to induce anesthesia for the procedure.
Who demonstrated the procedure?
Keara Healy and Stephanie Daugherty, research technicians, demonstrated the procedure.
What are the implications of this research?
It may lead to new insights into the mechanisms controlling bladder function.
Is this technique applicable to other areas of research?
Yes, it could be adapted for studies on other organs and tissues.
Executive Industry Relevance
Direct in vivo measurement of distension-evoked urothelial ATP release in rodents provides a physiologically relevant platform for interrogating purinergic signaling mechanisms in the urinary bladder. This approach enables mechanistic de-risking and target validation for sensory pathways implicated in bladder function, supporting predictive confidence at early discovery inflection points. The method's quantitative outputs facilitate robust portfolio triage and translational continuity for programs targeting bladder sensory modulation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of purinergic signaling pathways under physiological conditions.
- Supports functional target validation by quantifying ATP release in response to mechanical and chemical stimuli.
- Facilitates mechanistic de-risking for sensory targets in bladder research.
- Provides quantitative data to inform predictive confidence and portfolio triage.
Screening & Assay Development
- Establishes a validated in vivo system for measuring ATP release suitable for downstream screening workflows.
- Delivers reproducible, quantitative outputs via luciferin-luciferase assay for assay standardization.
- Enables assessment of pharmacological modulators by incorporating agonists or antagonists into the perfusate.
- Supports reliable evaluation of compound effects on urothelial ATP release.
Translational & Preclinical Research
- Aligns with disease-relevant models by maintaining intact bladder physiology during measurement.
- Enables comparison between wildtype and genetically modified animals for translational biomarker exploration.
- Supports risk-adjusted advancement decisions by providing mechanistic insights into bladder sensory pathways.
- Facilitates continuity from discovery through preclinical validation for bladder-targeted programs.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling hypothesis testing, pathway clarification, and quantitative assessment of sensory signaling in the bladder.
- Discovery Biology: Supports hypothesis-driven interrogation of ATP-mediated signaling and mechanistic de-risking.
- Screening: Provides assay-ready, reproducible, and quantitative ATP measurements for compound evaluation.
- Analytics: Delivers standardized readouts and statistical outputs for cross-condition comparison.
- Translational Research: Maintains physiological relevance and enables biomarker alignment in disease-relevant models.
- Enterprise Reuse: Offers a reusable platform for studying distension-evoked release of other molecules with suitable assays.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in bladder sensory research.
- Operational Value: Standardizes measurement protocols and enhances reproducibility across studies.
- Strategic Value: Informs go/no-go decisions and improves capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of bladder-targeted assets.
Implementation Considerations
- Requires expertise in rodent surgical techniques and in vivo physiology.
- Needs access to pressure transducers, perfusion systems, and luminometer-based ATP quantification infrastructure.
- Demands rigorous cross-team standardization of assay conditions and data analysis.
- Adaptation to other model systems or analytes depends on assay compatibility and physiological relevance.
- Susceptibility of luciferin-luciferase assay to chemical interference necessitates careful control selection and standard curve validation.
Biopharma FAQs
Why does null hypothesis testing matter for ATP quantification in bladder distension?
Null hypothesis testing enables objective evaluation of whether distension or pharmacological interventions significantly alter urothelial ATP release, supporting robust target validation and mechanistic de-risking in discovery workflows.
How does independent variable isolation fit the ATP release measurement pipeline?
Isolating variables such as mechanical distension or specific drug treatments allows precise attribution of observed ATP changes to defined stimuli, enhancing predictive confidence and assay interpretability for R&D teams.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative ATP measurements via luciferin-luciferase assay provide standardized, reproducible outputs that facilitate cross-condition comparisons and inform data-driven advancement decisions in the discovery pipeline.
Why are replication requirements critical for cross-functional collaboration in ATP assays?
Replication ensures that ATP release findings are robust and reproducible across experiments and teams, supporting cross-functional confidence in assay outputs and enabling reliable portfolio triage.
What statistical analysis capabilities are required before implementing ATP release assays?
Statistical analysis must include standard curve generation, non-linear regression, and appropriate controls to ensure accurate ATP quantification and to validate assay sensitivity and specificity for R&D decision-making.
Chapters in this video
0:05
Introduction
0:35
Anesthesia and Ganglionic Block
1:29
Surgical Procedure: Suprapubic Bladder Catheterization
2:29
Transurethral Catheterization
3:43
Experimental Setup
5:08
Collection of Samples
6:20
Quantifying ATP from Collected Samples
7:03
Results: Measurement of Urothelial ATP Release In Vivo from the Lumen of the Bladder
8:39
Conclusion
